Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6596780 | 0.92 | HTR1D (0.56) | SLC6A4DRD2HTR1DHTR1BOPRM1 | |
| SCHEMBL7089113 | 0.91 | OPRM1 (0.47) | SLC6A4DRD2HTR1DHTR1BOPRM1 | |
| SCHEMBL27541443 | 0.84 | APP (0.50) | SLC6A4DRD2OPRM1OPRK1OPRL1 | |
| SCHEMBL6598375 | 0.83 | HTR1D (0.54) | SLC6A4DRD2HTR1DHTR1B | |
| SCHEMBL6597826 | 0.82 | HTR1D (0.56) | SLC6A4DRD2HTR1DHTR1BOPRM1 | |
| SCHEMBL6593968 | 0.82 | OPRM1 (0.54) | SLC6A4DRD2HTR1DHTR1BOPRM1 | |
| SCHEMBL6596683 | 0.81 | DRD2 (0.46) | DRD2HTR1DHTR1BKCNH2 | |
| SCHEMBL6598294 | 0.81 | HTR1D (0.45) | SLC6A4DRD2HTR1DHTR1B | |
| SCHEMBL6596945 | 0.80 | CCR2 (0.44) | SLC6A4DRD2HTR1DHTR1B | |
| SCHEMBL31143224 | 0.80 | ADRA1D (0.57) | SLC6A4DRD2OPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1264838-C | Indole derivatives for treating central nervous system disease | LUNDBECK & CO AS H (DK) | 2006-07-19 | — | — | CN | disclosed |
| US-6743809-B2 | Indole Derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2004-06-01 | — | — | US | disclosed |
| EP-1305307-B1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2004-05-06 | — | — | EP | disclosed |
| CN-1451002-A | Indole derivatives for treating central nervous system disease | LUNDBECK & CO AS H (DK) | 2003-10-22 | — | — | CN | disclosed |
| US-20030166664-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166664-A1 | Indole derivatives useful for the treatment of CNS disorders | DRD2, DRD3, CNR1 | SLC6A4 58/4885DRD2 1/4885HTR1D 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.